MedTrace Logo

Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;

NCT04586972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 977

Last updated 2025-09-16

No results posted yet for this study

Summary

The main objective of this study is to realize an observational "real life" study conducted in French geriatric settings, to assess safety and efficacy in ≥ 80 year-old patients with nonvalvular Atrial fibrillation (AF) newly treated with Apixaban.

Moreover, in this geriatric population the adequacy of Apixaban dosage and events (bleeding and stroke) will be assessed.

Conditions

  • Nonvalvular Atrial Fibrillation

Sponsors & Collaborators

  • Gérond'if

    lead OTHER

Principal Investigators

  • Olivier Hanon, MD PhD · Geriatric Department, Broca hospital

Eligibility

Min Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-23
Primary Completion
2023-12-21
Completion
2024-04-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04586972 on ClinicalTrials.gov